Sinovac's history dates back to 1993 when its Chief Executive Officer Yin Weidong and a team at Tangshan Yian Biological Engineering Co Ltd engaged in research and development that lead to production of a hepatitis A vaccine in 1999. It is the first of its kind developed by Chinese scientists.
Over the past two decades, the company has developed and commercialized five human-use vaccines and advanced its R&D pipeline. The company has achieved many significant development milestones that exemplify its core R&D competencies, inclusive of developing the first H1N1 vaccine in the world in 2009.
Moreover, it has expanded an integrated platform with state-of-the-art research facilities, GMP certified manufacturing facilities, and a sales team with reach across China.
Sinovac's Key Milestones
2010
Established Sinovac (Dalian) Vaccine Technology Co Ltd Completed acquisition of Changping buildings and land Submitted clinical trial application for mumps vaccine to SFDA
2009
Moved to NASDAQ Global Market Granted production license for Panflu.1 and received orders for 12.49 million doses Submitted clinical trial application to SFDA for EV71 vaccine
2005
Bilive and Anflu approved
2004
Acquisition of Tangshan Yi'An Transfer to listing on AMEX 2003 Reverse merger with US OTCBB
2002
Launch of flagship product, Healive 2001 Sinovac Biotech founded in Beijing
Sinovac's mission is to supply vaccines against human diseases.
Its goals are to:
Provide children, adults and the elderly with international quality vaccines
Provide children around the world with vaccines made in China
To achieve these objectives, Sinovac focuses on research, development, manufacturing and marketing of human-use and animal-use vaccines. It also provides services for disease control and prevention as it collaborates with the Chinese central government at the national, state and local levels.
When people expect a vaccine to control diseases as part of routine healthcare and during emergency situations, Sinovac stands out as a leading provider of high quality vaccines.
